Announced details
Enables the fabrication of larger tissues. Automates the process from dispensing to layering cell aggregates within a biosafety cabinet. Specific figures: Not disclosed.
The companies began collaborating in 2022 on the mechanization and automation of the manufacturing process for 3D cell products and have been advancing their joint development in stages.
Head office: Shinagawa-ku, Tokyo; Representative Director: Ichii Akitoshi (市井明俊). Founded in 1916. The company operates in bearings, automotive components and precision machinery products, with bases in approximately 30 countries. It is described as the world's third-largest bearing manufacturer.
Sales and deployment of this device are planned, but the specific financial impact is Not disclosed.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | New bio 3D printer, S-PIKE® |
| Counterparty | NSK Ltd. |
| Counterparty overview | Head office: Shinagawa-ku, Tokyo; Representative Director: Ichii Akitoshi (市井明俊). Founded in 1916. The company operates in bearings, automotive components and precision machinery products, with bases in approximately 30 countries. It is described as the world's third-largest bearing manufacturer. |
| Relationship with the Company | The companies began collaborating in 2022 on the mechanization and automation of the manufacturing process for 3D cell products and have been advancing their joint development in stages. |
| Applicable area | Regenerative Medicine, Cell therapy, 3D cell products, Functional Foods, Cosmetics |
| Quantitative Effects | Enables the fabrication of larger tissues. Automates the process from dispensing to layering cell aggregates within a biosafety cabinet. Specific figures: Not disclosed. |
| Impact on Business Performance | Sales and deployment of this device are planned, but the specific financial impact is Not disclosed. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To scale up products, compact and automate the manufacturing process, and establish a stable production system for the future commercial production of regenerative medicine and 3D cell products.